Apogee Therapeutics (APGE) Stifel 2024 Immunology and Inflammation Virtual Summit summary

Company and pipeline overview

• Focused on developing best-in-class antibodies for large inflammation and immunology markets, with a lead IL-13 inhibitor in phase II targeting atopic dermatitis.

• Pipeline includes IL-4 receptor alpha, OX40 ligand, and TSLP, supporting first-in-class combination therapies for Type 2 inflammation.

• Recently appointed a new Chief Commercial Officer to strengthen commercial strategy.

APG-777 program and clinical data

• APG-777 is a highly engineered IL-13 antibody with a 75-day half-life, enabling dosing every 3–6 months and higher concentration formulation.

• Phase I data showed a well-tolerated safety profile, dose proportionality, and low variability, with near-complete and prolonged inhibition of key biomarkers (p-STAT6 and TARC) for up to 12 weeks.

• Phase II trial combines proof-of-concept and dose optimization in a single protocol, aiming to accelerate timelines toward BLA and includes a maintenance phase.

• The trial is powered with 110 patients for robust efficacy readout at 16 weeks, aligning with industry standards for atopic dermatitis endpoints.

• Higher exposure regimens are being tested, with the potential for improved efficacy and reduced injection burden compared to existing therapies.

Market landscape and commercial insights

• The atopic dermatitis market is significantly underserved, with biologic penetration still low despite its large size.

• Recent approval of lebrikizumab in the U.S. is expected to drive further adoption of biologics, with less frequent dosing seen as a transformative advantage.

• Every 3–6 month dosing is considered highly desirable by both patients and physicians, even with efficacy similar to current standards.